The state of Minnesota currently has 39 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Minneapolis, Rochester, Saint Paul and Duluth.
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
Recruiting
This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period. Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients with CFRD to support a future larger randomized controlled trial.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/03/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Cystic Fibrosis-related Diabetes, Cystic Fibrosis
A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes
Recruiting
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Type 2 Diabetes Treated With Insulin
Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Dail... Read More
Gender:
All
Ages:
Between 2 years and 80 years
Trial Updated:
01/18/2024
Locations: Initernational Diabetes Center, Minneapolis, Minnesota +2 locations
Conditions: Type 1 Diabetes
Diabetes in African Youth
Recruiting
This RCT aims to improve T1D care in East African children and young adults by testing the hypothesis that enabling patients to continuously monitor glucose levels with flash CGM technology will improve glucose time-in-range (glucose level 70-180 mg/dl). A second primary endpoint is to perform a cost analysis on flash glucose monitoring compared to 3x/day SMBG, to determine whether this technology is cost-effective in the setting of a less-resourced nation. After a 2 week assessment with blinde... Read More
Gender:
All
Ages:
Between 4 years and 26 years
Trial Updated:
12/28/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: type1diabetes
TrialNet Pathway to Prevention of T1D
Recruiting
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T... Read More
Gender:
All
Ages:
Between 30 months and 45 years
Trial Updated:
12/20/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Diabetes Mellitus, Type 1
STOP-T1D Low-Dose (ATG)
Recruiting
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
Gender:
All
Ages:
Between 12 years and 34 years
Trial Updated:
12/14/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Diabetes Mellitus, Type 1
Type 1 Diabetes Extension Study
Recruiting
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: follow participants to determine how long they continue to produce insulin, and will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for typ... Read More
Gender:
All
Ages:
Between 8 years and 35 years
Trial Updated:
12/06/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Type 1 Diabetes Mellitus, T1DM, T1D
A Study of Glycemic Control in Left Ventricular Assist
Recruiting
The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sug... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/04/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Type 2 Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Recruiting
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/22/2023
Locations: HealthPartners Institute, Bloomington, Minnesota
Conditions: Type 2 Diabetes Mellitus, Cardiovascular Diseases
The Effects of Glucagon on Hepatic Metabolism
Recruiting
Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important, unanswered questions. NAFLD is associated with T2DM risk and impaired insulin action. Unfortunately, it is unclear if glucagon resistance is caused by obesity, hepatic steatosis or both. The experiments outlined will determine if glucagon's actions on hepatic amino acid... Read More
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
11/01/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Obesity, Type2diabetes, NAFLD
My Diabetes Study - CGM Initiation Approach & Time In Range
Recruiting
This study includes two phases. The purpose of Phase 1 of this study is to understand if there is a difference between two ways of introducing a continuous glucose monitor (CGM) to people with type 2 diabetes (T2D). The study will evaluate the effect of using a nutrition-focused approach (NFA) versus a self-directed approach (SDA) during CGM initiation on time in range (TIR) glucose. TIR is the percent of time that someone's glucose is between 70 and 180 mg/dL. It is possible that the approach u... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: HealthPartners Institute dba International Diabetes Center, Minneapolis, Minnesota
Conditions: Type 2 Diabetes
Butyrate Adjuvant Therapy for Type 1 Diabetes
Recruiting
The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
Gender:
All
Ages:
Between 20 years and 80 years
Trial Updated:
10/03/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Type1diabetes